Kit device
Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335
Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization
IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data
IDRx, KIT inhibitor, pivotal study, funding, cancer treatment, biotech